Compounds of formulae (I) and (II) are disclosed as 5-HTinhibitors. Those compounds that exhibit central activity are useful in treating chemotherapy-induced nausea and vomiting (CINV); those that peripheral receptors are useful to treat diarrhea-predominant Irritable Bowel Syndrome (IBS-D).